Switch theme
Sign up to access all valuation multiples
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.
2008
2.6K+
LTM Revenue $949M
LTM EBITDA $7.1M
$1.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Tandem Diabetes Care has a last 12-month revenue (LTM) of $949M and a last 12-month EBITDA of $7.1M.
In the most recent fiscal year, Tandem Diabetes Care achieved revenue of $940M and an EBITDA of -$69.8M.
Tandem Diabetes Care expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Tandem Diabetes Care valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $949M | XXX | $940M | XXX | XXX | XXX |
| Gross Profit | $493M | XXX | $490M | XXX | XXX | XXX |
| Gross Margin | 52% | XXX | 52% | XXX | XXX | XXX |
| EBITDA | $7.1M | XXX | -$69.8M | XXX | XXX | XXX |
| EBITDA Margin | 1% | XXX | -7% | XXX | XXX | XXX |
| EBIT | -$111M | XXX | -$99.1M | XXX | XXX | XXX |
| EBIT Margin | -12% | XXX | -11% | XXX | XXX | XXX |
| Net Profit | -$126M | XXX | -$96.0M | XXX | XXX | XXX |
| Net Margin | -13% | XXX | -10% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $280M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Tandem Diabetes Care's stock price is $20.
Tandem Diabetes Care has current market cap of $1.3B, and EV of $1.4B.
See Tandem Diabetes Care trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.4B | $1.3B | XXX | XXX | XXX | XXX | $-1.43 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Tandem Diabetes Care has market cap of $1.3B and EV of $1.4B.
Tandem Diabetes Care's trades at 1.5x EV/Revenue multiple, and -20.7x EV/EBITDA.
Equity research analysts estimate Tandem Diabetes Care's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Tandem Diabetes Care has a P/E ratio of -10.5x.
See valuation multiples for Tandem Diabetes Care and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.3B | XXX | $1.3B | XXX | XXX | XXX |
| EV (current) | $1.4B | XXX | $1.4B | XXX | XXX | XXX |
| EV/Revenue | 1.5x | XXX | 1.5x | XXX | XXX | XXX |
| EV/EBITDA | 203.8x | XXX | -20.7x | XXX | XXX | XXX |
| EV/EBIT | -13.0x | XXX | -14.6x | XXX | XXX | XXX |
| EV/Gross Profit | 2.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | -10.5x | XXX | -13.7x | XXX | XXX | XXX |
| EV/FCF | -130.2x | XXX | -34.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialTandem Diabetes Care's last 12 month revenue growth is 11%
Tandem Diabetes Care's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.
Tandem Diabetes Care's rule of 40 is -16% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Tandem Diabetes Care's rule of X is 27% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Tandem Diabetes Care and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Margin | 1% | XXX | -7% | XXX | XXX | XXX |
| EBITDA Growth | 566% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -16% | XXX | 3% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 27% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 21% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 63% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Tandem Diabetes Care acquired XXX companies to date.
Last acquisition by Tandem Diabetes Care was XXXXXXXX, XXXXX XXXXX XXXXXX . Tandem Diabetes Care acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Tandem Diabetes Care founded? | Tandem Diabetes Care was founded in 2008. |
| Where is Tandem Diabetes Care headquartered? | Tandem Diabetes Care is headquartered in United States of America. |
| How many employees does Tandem Diabetes Care have? | As of today, Tandem Diabetes Care has 2.6K+ employees. |
| Who is the CEO of Tandem Diabetes Care? | Tandem Diabetes Care's CEO is Mr. John F. Sheridan. |
| Is Tandem Diabetes Care publicy listed? | Yes, Tandem Diabetes Care is a public company listed on NAS. |
| What is the stock symbol of Tandem Diabetes Care? | Tandem Diabetes Care trades under TNDM ticker. |
| When did Tandem Diabetes Care go public? | Tandem Diabetes Care went public in 2013. |
| Who are competitors of Tandem Diabetes Care? | Similar companies to Tandem Diabetes Care include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Tandem Diabetes Care? | Tandem Diabetes Care's current market cap is $1.3B |
| What is the current revenue of Tandem Diabetes Care? | Tandem Diabetes Care's last 12 months revenue is $949M. |
| What is the current revenue growth of Tandem Diabetes Care? | Tandem Diabetes Care revenue growth (NTM/LTM) is 11%. |
| What is the current EV/Revenue multiple of Tandem Diabetes Care? | Current revenue multiple of Tandem Diabetes Care is 1.5x. |
| Is Tandem Diabetes Care profitable? | Yes, Tandem Diabetes Care is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Tandem Diabetes Care? | Tandem Diabetes Care's last 12 months EBITDA is $7.1M. |
| What is Tandem Diabetes Care's EBITDA margin? | Tandem Diabetes Care's last 12 months EBITDA margin is 1%. |
| What is the current EV/EBITDA multiple of Tandem Diabetes Care? | Current EBITDA multiple of Tandem Diabetes Care is 203.8x. |
| What is the current FCF of Tandem Diabetes Care? | Tandem Diabetes Care's last 12 months FCF is -$11.1M. |
| What is Tandem Diabetes Care's FCF margin? | Tandem Diabetes Care's last 12 months FCF margin is -1%. |
| What is the current EV/FCF multiple of Tandem Diabetes Care? | Current FCF multiple of Tandem Diabetes Care is -130.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
